NCT05189405 is a clinical trial of INVOcell IVC in Infertility, sponsored by INVO Bioscience, Inc..

Who is sponsoring NCT05189405?

NCT05189405 is sponsored by INVO Bioscience, Inc..

What drugs are being tested in NCT05189405?

Interventions in NCT05189405: INVOcell IVC.

What condition does NCT05189405 study?

NCT05189405 studies Infertility.

Is NCT05189405 still recruiting?

NCT05189405 is currently status unknown. Last updated 12 January 2022.

Last reviewed 2022-01-12 · How we verify

NCT05189405

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3 Year Retrospective Analysis of IVF in Comparison With INVOcell

Status unknown Last updated 12 January 2022

What this trial tests

trial testing INVOcell IVC in Infertility in 450 participants. Status unknown.

Timeline

12 October 2021

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	INVO Bioscience, Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	12 October 2021
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	4 locations across United States

Drugs / interventions tested

INVOcell IVC

Conditions studied

Infertility — all drugs for Infertility →

Sponsor

INVO Bioscience, Inc.

Who can join

Adults 18 to 42, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective chart review of data on the use of traditional IVF and INVOcell IVC collected from clinics using both technologies. The retrospective data will be utilized for a comparison of the two methods.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other INVO Bioscience, Inc. trials

Trials by the same sponsor.

NCT04644380 — Assessment of the INVOcell Culture Device When Used for up to Five-Day Incubation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05189405 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by INVO Bioscience, Inc.
Last refreshed: 12 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing